

LUCENCE

This pamphlet is not intended for the purpose of providing medical advice. All information, content, and material of this pamphlet are for informational purposes only and are not intended to serve as a substitute for the consultation, diagnosis, and/or medical treatment of a qualified physician or healthcare provider. Always seek the advice of your physician or other qualified healthcare provider for information you may need regarding a medical condition.

www.lucence.com

Customer support:

Singapore

+65 6592 5102
sales.asean@lucence.com

Hong Kong

+852 5182 7199
sales.hk@lucence.com

Lucence Service Laboratory

211 Henderson Road #04-01/02,
Henderson Industrial Park,
Singapore 159552

Lucence Diagnostics Pte. Ltd.
is licensed by the Ministry of Health (Singapore) as a
Clinical Laboratory (License Number: L/1710039/CLB/004/242)
under the Healthcare Services Act 2020.
GST Registered 201605840N.

50 Cancers in 1 Blood Test Earlier Cancer Detection Saves Lives



LucenceINSIGHT®

Patient Information Leaflet

LUCENCE

Why Screen for Cancer?


#2 Cause of Death globally¹

8 in 10 Cancer Deaths are not covered by conventional screening^{2*}

52.8% of All Cancers are diagnosed at late stage³

*Only colorectal, cervical, and breast cancer are recommended for screening in Singapore and Hong Kong (HealthHub. Screen for Life. Singapore Ministry of Health. <https://www.healthhub.sg/programmes/healthiersg-screening/screening-faq#home>. Accessed September 15, 2025; Hong Kong Cancer Registry. Prevention and screening. https://www.cancer.gov.hk/en/hong_kong_cancer/prevention_and_screening.html#3. Accessed September 15, 2025.)References: [1] Cancer. World Health Organization. Accessed August 1, 2025. https://www.who.int/health-topics/cancer#tab=tab_1. [2] Calculated based on colorectal, cervical and breast cancer data (Bray, F. et al. CA Cancer J. Clin. 2024; 74(3): 229-263) [3] Late Stage is defined as Stage III + IV (Zeng H, et al. Lancet 2021; 6(12): e877-e887)

Earlier Detection is Associated with Better Survival




Reference: [5] Statistics derived from data reported in Cancer Stat Facts. NIH NCI SEER. Accessed July 28, 2025. <https://seer.cancer.gov/statfacts/>.

What is LucenceINSIGHT®?

LucenceINSIGHT® is a multi-cancer early detection (MCED) test that detects and analyzes circulating tumor nucleic acids released from cancer cells.

LucenceINSIGHT® screens for the signal of up to **50** cancers in **1** blood draw.



References: [6] Cumulative risk of 43.1% false positives over 14 screening exams from other tumor marker screening methods including chest radiograph, flexible sigmoidoscopy, CA-125, and transvaginal ultrasonography for women, and chest radiograph, flexible sigmoidoscopy, PSA, and DRE for men. (Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212-222.) [7] Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042.

Case Study Early Detection of Colorectal Cancer



A cancer signal was detected in a 60+ year-old asymptomatic patient



PET-CT scan and colonoscopy confirmed early stage colorectal cancer



The patient underwent surgery to remove tumors and was discharged

Disclaimer: The case study is for educational, scientific presentation purposes only, and individual case outcomes and results may vary. The image, case detail, or other descriptions of the case are provided directly by the treating physician/oncologist in a de-identified manner and reproduced with express permission of the treating physician/oncologist.

Comprehensive Screening of 50 Cancers

LucenceINSIGHT® 50

Eye cancer
(Conjunctival melanoma; Uveal melanoma)

Head & Neck

Nasopharyngeal cancer (EBV+)
Oropharyngeal cancer
(HPV-positive; HPV-negative)
Laryngeal cancer
Salivary gland cancer

Thyroid cancer
Breast cancer
Lung cancer
Lung neuroendocrine tumor

Digestive

Esophageal cancer
Liver cancer
Stomach cancer
Stomach neuroendocrine tumor
Pancreatic cancer
Biliary tract cancer
(Intrahepatic, Extrahepatic, Gall bladder)
Gastrointestinal stromal tumor
Small intestine cancer
Colorectal cancer
Colorectal neuroendocrine tumor

Gynecologic

Cervical cancer
Endometrial cancer
Ovarian cancer
Ovarian germ cell & stromal tumors
Vulvar cancer

Lymphoid

Non-Hodgkin lymphoma
(Burkitt's lymphoma;
Diffuse large B-cell lymphoma;
Lymphoplasmacytic lymphoma)
Hairy cell leukemia

Myeloid

Acute myeloid leukemia (AML)
(myelodysplasia-related;
NPM1-mutation;
other defined genetic alterations)
Myeloproliferative neoplasm
Mast cell tumor
Myeloma


Musculoskeletal

Bone cancer
Soft tissue
(Angiosarcoma;
Smooth muscle sarcoma)

Genitourinary

Adrenal gland cancer
Kidney cancer (clear cell)
Adult Wilms tumor
Bladder cancer
Penile cancer
Prostate cancer
Testis cancer


Skin cancer
(Melanoma; Non-melanoma)



For Women

LucenceINSIGHT® 12

LucenceINSIGHT® Women's 7




 Cancer coverage for LucenceINSIGHT® Women's 7

For Men

LucenceINSIGHT® 12

LucenceINSIGHT® 5



 Cancer coverage for LucenceINSIGHT® 5

Who Can Benefit from LucenceINSIGHT®

Individuals Aged 40+

OR

Elevated Cancer Risk

(family history, diet, lifestyle)

Not recommended for patients who are:

- Pregnant
- In cancer remission for < 3 years
- Had surgery, an allogenic bone transplant or a blood transfusion < 2 weeks prior to sample collection

Ordering Process



**Test is
Requested
by Your
Healthcare
Provider**



Blood draw
Refrain from
heavy meals
prior to blood
collection.



Lab testing



Report

The report will be ready 15-18 working days
after sample is accepted by the lab

